PFE · News · 20260921N

Licensing / Collaboration Deals

PFIZER INC · 2026-09-21 · Importance 30 · Surprise 42

Pfizer entered an in-licensing deal with Medicus Pharma for the CD228V antibody-drug conjugate (ADC). The transaction followed Pfizer’s reprioritization of the asset after its Seagen acquisition, and Medicus obtained sublicensing rights. The deal is intended to support development of CD228V within Medicus’s oncology platform and potential future monetization through partnerships.

Key facts